Fifteen patients (71%) had NTRK gene rearrangements and 6 patients (29%) harbored a ROS1 gene fusion as entrectinib has efficacy in ROS1 fusion positive NSCLC. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.